Article
In this video, Dr. Eric Ruderman looks at abstracts #0884, #0323 and #0909, which focus on disease activity measurement in psoriatic arthritis, presented at the 2020 ACR Convergence meeting earlier this month.
All News
Article
Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.
Dr. John Cush
Tweet
Dr. Conway ( @RichardPAConway) and Dr. Maguire discuss abstract #1323 presented at the #ACR20 on pregnancy in Spondyloarthritis.
https://t.co/YyWOuiq3jn https://t.co/SnodUbKZTx
Dr. John Cush
Tweet
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20
https://t.co/5Qg3HRkQyW https://t.co/x0iQ6XX3eJ
Dr. John Cush
Tweet
#BestACR20Tweets
RT @MeralElRamahiMD : Wonder if you can predict development of clinical RA in those at risk either w/ a
- +RF or +CCP
- Relevant sxs w/ or w/o abs
- 1st deg relatives do RA pts?
#ACR20 https://t.co/xVZHxL35UY
Dr. John Cush
Tweet
#BestACR20Tweets
RT @RADoctor: Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Dr. John Cush
Tweet
New video! Risk of HCQ Retinopathy: Dr. Kathryn Dao ( @KDAO2011) #ACR20
https://t.co/7BCVvMOm0T https://t.co/DOW91SSi2u
Dr. John Cush
Tweet
#BestACR20Tweets
"RT @drdavidliew : This - very cool.
Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see!
#ACR20 ABST1995 @RheumNow https://t.co/cE3gQar0zo https://t.co/bmGnrMGaq3
Dr. John Cush
Tweet
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate.
https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y
Dr. John Cush
Tweet
Revisit our #ACR20 coverage. Listen to our Day 3 recap. Follow the link below or find us on Apple/Android podcasts.
https://t.co/IbfY5vbBAo https://t.co/YL9fAuO0oz
Dr. John Cush
Tweet
#BestACR20Tweets
RT @DrPetryna : #ACR20 Abs L08 Prosp. 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat not associated w/increased risk of death compared w/allopurinol.7.2% pts died in the febuxostat group compared to 8.6% in the allopurinol group
Dr. John Cush
Tweet
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup by Dr. Robert Chao ( @doctorRBC) #ACR20
https://t.co/wR0inoR8jp https://t.co/7SFkThkPSr
Dr. John Cush
Tweet
#BestACR20Tweets
RT @doctorRBC : Mavrilimumab efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
Disease flare 19% in tx vs. 46% in PBO at 26wk
Sustained remission 83% vs. 50% in PBO
Similar AE in both groups Abs#L06
https://t.co/fsZxZVmDIu" https://t.co/j17naatAxX
Dr. John Cush
Tweet
Listen to our latest QD podcast on differential Dx of Arthritis in HIV+ individuals, possibilities with hyperuricemia in Psoriatic Arthritis MDA5 myositis reviewed, difficult RA with serious infections and limited options.
https://t.co/HGjgkMmOzp https://t.co/jFs8kINS3U
Dr. John Cush
Tweet
New ACR RA Guidelines and Practice Changing Abstracts #ACR20
https://t.co/3lGSUDks8F
Dr. John Cush
Tweet
Listen now! Dr. Jack Cush leads a panel of experts regarding Still's Disease and #ACR20. Download our podcasts on Apple and Android devices.
https://t.co/eV5jR0BIXO https://t.co/IChHpeiI9x
Dr. John Cush
Tweet
Listen as Dr. Petryna ( @DrPetryna) reviews several pegloticase-related abstracts presented at the #ACR20 meeting.
https://t.co/TBi1uRPXG0 https://t.co/wAUNr4mq1v
Dr. John Cush
Tweet
#BestACR20Tweets
RT @bella_mehta : VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/IEC8IfE0LC https://t.co/jV3EYK0NUK
Dr. John Cush
Tweet
Long-Term Prognosis in Children with Kawasaki Disease: Dr. David Liew ( @drdavidliew) #ACR20
https://t.co/Hg8nYWcD3V https://t.co/pJIGNMnRss
Dr. John Cush
Tweet
#BestACR20Tweets
RT @TheLancetRheum: Results of the NOVESA phase 2 trial of Ziritaxestat in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20
Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. https://t.co/GCZj64i86c https://t.co/Pd6qGEGOev
